Key result
A cumulative anthracycline dose of ≥460 mg/m² significantly increased the risk of late subclinical cardiotoxicity in childhood acute myeloid leukemia survivors compared to lower doses (HR 3.42).
Cohort (n=185)
Yes
Hazard Ratio: 3.42 (95% CI 1.1–10.72)
Absolute Event Rate: 37% vs 15%
p-value: p=0.035
Childhood AML survivors face a substantial risk of late cardiotoxicity, reaching 27% at 15 years, highlighting the need for long-term cardiac monitoring.
No takes yet. Share an insight, caveat, or question.
May guide anthracycline dosing in childhood AML survivors; leaves open prospective validation of thresholds.
Barlogis et al. (2015) conducted a cohort in Childhood acute myeloid leukemia (AML) survivors (n=185). Cumulative anthracycline dose ≥460 mg/m² vs. Cumulative anthracycline dose <460 mg/m² was evaluated on Subclinical cardiotoxicity (SCC) (HR 3.42, 95% CI 1.10-10.72, p=0.035). A cumulative anthracycline dose of ≥460 mg/m² significantly increased the risk of late subclinical cardiotoxicity in childhood acute myeloid leukemia survivors compared to lower doses (HR 3.42).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: